VF
OMED

Virtu Financial’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Virtu Financial’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-12,843
Closed -$30K – 2619
2018
Q2 		$30K Buy
+12,843
New +$37.4K ﹤0.01% 1828
2018
Q1 		– Sell
-41,395
Closed -$170K – 3132
2017
Q4 		$170K Buy
+41,395
New +$180K 0.01% 1750

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Virtu Financial's OMED Position: Q3 2018 in Review

Virtu Financial sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q3 2018, closing a stake of 12,843 shares — an estimated $30K sold.

Virtu Financial first reported a position in OMED in Q4 2017 and held it in 2 quarters. The position peaked at $170K in Q4 2017. 54 funds tracked by Wall St. Rank hold OMED as of Q3 2018.

  • Virtu Financial reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • Virtu Financial sold 12,843 OncoMed Pharmaceuticals, Inc. shares in Q3 2018, an estimated $30K.
  • Virtu Financial first reported a position in OncoMed Pharmaceuticals, Inc. in Q4 2017 and held it in 2 quarters.
  • Virtu Financial's OncoMed Pharmaceuticals, Inc. position peaked at $170K in Q4 2017.
  • 54 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q3 2018.

Based on Virtu Financial's 13F filing for Q3 2018, filed 13 Nov 2018.